Latest in Lilly Shares Jump
Sort by
546 items
-
Eli Lilly shares jump on two big updates and Jim Cramer is so here for it
The Biden administration proposed a rule change that would expand access to Eli Lilly's Zepbound. And an obesity drug competitor released disappointing results.Business - CNBC - 17 hours ago -
Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales
US group revises down upper end of full-year revenue estimatesBusiness - Financial Times - October 30 -
Amazon shares jump 6% after earnings beat
Amazon's latest upbeat results were driven by growth in cloud and digital advertising.Business - CNBC - November 1 -
Palantir shares close up 23% to record on uplifting guidance
Palantir shares soared to a record on Tuesday after the software company reported better-than-expected results and issued uplifting guidance.Business - CNBC - November 5 -
Lyft shares soar 20% on results and autonomous-vehicle partnership
Lyft reported third-quarter sales that beat expectations while offering an upbeat demand forecast, after the ride-hailing platform earlier in the day announced an autonomous-vehicle partnership ...Business - MarketWatch - November 7 -
Jim Cramer identifies an interesting buy level for our worst performing Big Tech stock this year
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.Business - CNBC - October 31 -
Snap shares jump after results come in better than expected
Shares of Snap Inc. rose after hours on Tuesday after the social-media platform reported third-quarter results that beat expectations and said its board authorized a stock buyback of up to $500 ...Business - MarketWatch - October 30 -
Snap shares jump 10% on profit beat, stock buyback
Snap reported third-quarter results on Tuesday that beat on the top and bottom lines, but the company issued light fourth-quarter guidance.Business - CNBC - October 29 -
Intel shares jump 7% on earnings beat, uplifting guidance
Intel reported better-than-expected earnings following a quarter filled with challenges.Business - CNBC - October 31 -
Palantir’s shares jump as ‘unwavering demand’ for AI lifts earnings
Peter Thiel’s data analytics company raises its revenue forecast as growth acceleratesBusiness - Financial Times - November 4 -
Novo Nordisk shares jump 8% after Wegovy sales beat expectations
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.Business - CNBC - November 6 -
Yeti Shares Climb on Jump in Third-Quarter Cooler, Drinkware Sales
The maker of coolers and insulated drinkware expects to hit the high end of its earnings guidance for the year after posting a bigger profit and higher-than-estimated sales in the third quarter.Business - The Wall Street Journal - November 7 -
Nissan shares jump after activist investor takes stake
Hedge fund Effissimo Capital is known for high-profile campaigns against big Japanese companiesWorld - Financial Times - November 12 -
Swiggy's Shares Jump in India's Second-Largest IPO This Year
Shares of Indian startup Swiggy surged at its Mumbai debut, driven by strong institutional interest in the food and grocery delivery company.Business - The Wall Street Journal - November 13 -
The US consumer is fine (but no better)
Aggregates conceal a lotWorld - Financial Times - November 20 -
Sage shares surge 19% as UK software group launches buyback
Financial software provider announces plan for £400mn share buyback and raises dividendWorld - Financial Times - November 20 -
Alibaba posts profit beat as China looks to prop up tepid consumer spend
The results come at a tricky time for Chinese commerce businesses, given the broad sluggishness in the world's second-largest economy.Business - CNBC - November 15 -
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.Business - MarketWatch - October 30 -
Eli Lilly's quarter was messy. What to do with the stock is more clear-cut
We're upgrading our rating on the drugmaker to a buy-equivalent 1.Business - CNBC - October 30 -
Lilly Sues U.S. to Change Hospital Drug Discount Payments
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain hospitals.Business - The Wall Street Journal - November 15 -
Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial
Eli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.Business - CNBC - November 19 -
Rising energy bills push inflation to highest for six months
Higher inflation pushes up the cost of living for households, and could mean that interest rates remain higher for longer.Top stories - BBC News - November 20 -
Airbnb misses on earnings but squeaks in a revenue beat
Airbnb reported third-quarter earnings Thursday that showed revenue up 10% year over year.Business - CNBC - November 7 -
Bitcoin, dollar and Tesla jump as investors pile into ‘Trump trades’
Markets expect US president-elect to take light-touch approach to regulationBusiness - Financial Times - November 11 -
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase manufacturing capacity.Business - CNBC - October 30 -
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly blamed the misses on drug wholesalers cutting inventory of Zepbound and Mounjaro.Business - CNBC - October 30 -
Here's why Eli Lilly bounced back, plus mega-caps lag while staples stocks rise
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.Business - CNBC - November 8 -
How we're thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS
Robert F. Kennedy Jr. has been a vocal critic of obesity drugs belonging to the fast-growing GLP-1 class.Business - CNBC - November 15 -
Alphabet Revenue Jumps 15% to $88.3 Billion
The tech giant’s 34 percent increase in quarterly profit topped Wall Street expectations, driven by its advertising and cloud businesses.Tech - The New York Times - October 29 -
UK borrowing costs hit post-election high on eve of Reeves’ first Budget
Chancellor will draw parallels with Tony Blair government’s efforts to repair country’s social fabric in late 1990sBusiness - Financial Times - October 30